Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
60 hedge funds and large institutions have $113M invested in Oyster Point Pharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.
1,092% more call options, than puts
Call options by funds: $143K | Put options by funds: $12K
29% more capital invested
Capital invested by funds: $87.6M → $113M (+$25M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 61 → 60 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$1.97M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$629K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$455K |
| 4 |
HF
HRT Financial
New York
|
+$263K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$524K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$449K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$220K |
OYST Hedge Fund Activity: Q3 2022 in Review
60 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q3 2022, worth a combined $113M — up 29% from $87.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OYST and 7 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 13 added.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $1.97M. The largest seller was Vanguard Group, cutting an estimated $1.5M.
- 60 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q3 2022, down from 61 in Q2 2022.
- Funds reported $113M of Oyster Point Pharma, Inc. Common Stock stock for Q3 2022, up 29% quarter-over-quarter.
- 7 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -1 holder.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q3 2022 was Paradigm Biocapital Advisors, an estimated $1.97M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2022.